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Abstract
Skin cancer is an increasingly frequent pathology, with a dangerous high percentage of 
malignant melanoma. The use of synthetic chemotherapy raises the problem of severe 
adverse effects and the development of resistance to treatment. Therefore, the use of 
natural therapies became the focus of numerous research groups due to their high effi-
cacy and lower systemic adverse effects. Among natural products evaluated as thera-
peutical agents against skin cancer, betulinic acid was emphasized as a highly selective 
anti-melanoma agent and is currently undergoing phase II clinical trials as topical 
application. Several other pentacyclic triterpenes exhibit antiproliferative activities. 
This chapter aims to present the latest main discoveries in the class of pentacyclic trit-
erenes with antitumor effect and the evolution of their preclinical trials. Furthermore, 
it includes reports on plant sources containing pentacyclic triterpenes, as well as the 
main possibilities of their water solubilization and cancer cell targeting. A review on 
recent data regarding mechanisms of action at cellular and molecular levels comple-
ments information on the outstanding medicinal potential of these compounds.
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1. Introduction
Skin cancer represents one of the most frequent cancers with an increasing incidence over 
the past decades [1]. Malignant melanoma, squamous cell carcinoma and basal cell car-
cinoma represent 98% of all skin cancers [2]. Malignant melanoma determines a higher 
mortality compared to nonmelanoma skin cancers, being responsible of 75% of skin cancer 
deaths [2, 3]. Sun exposure is one of the major risk factors, but it influences differently the 
types of skin cancer. Squamous cell carcinoma is more often related to chronic sun expo-
sure, while malignant melanoma is caused by intermittent sun exposure and overexposure 
in childhood [4].
Nonmelanoma skin cancer is considered to have the highest incidence of all cancers and 
occurs more frequently in people with white skin [5]. However, 232,000 new cases of malig-
nant melanoma were diagnosed in 2012, with the highest incidence in Australia. The number 
of deaths due to this type of skin cancer was 55,000 worldwide in the same year [6]. Malignant 
melanoma cases tripled in the last 30 years in the United States and Europe [1]. According 
to World Health Organization [7], each year occur 132,000 cases of melanoma skin cancers 
worldwide. The increasing incidence is associated with an increase of treatment costs. This 
aspect underscores the important role of prevention and early detection efforts for this type 
of cancer [8].
Even though numerous efforts were made for finding effective treatments in melanoma, 
prognosis for these patients remains unsatisfactory. The standard treatment in early stages is 
represented by surgical excision, followed by an adjuvant therapy or enrollment in a clinical 
trial [9]. An early detection of melanoma and a proper treatment increase the chances for cure. 
Surgery, chemotherapy, immunotherapy or radiation therapy can be used for the treatment 
[10]. Interferon-α (IFN-α) is used as an adjuvant therapy in patients with high-risk cutaneous 
melanoma, improving mainly disease-free survival but also overall survival, though not with-
out side effects [11]. An improvement of survival in patients with stage III melanoma has been 
noticed for ipilimumab therapy. This monoclonal antibody increases the immune response and 
is approved for treatment in advanced melanoma, but also causes gastrointestinal, endocrine 
and hepatic adverse effects [12]. New drugs have also been used in the treatment of patients 
with inoperable or stage IV cutaneous malignant melanoma. The BRAF inhibitors vemurafenib 
and dabrafenib, the anti-PD1 (programmed death 1) antibodies pembrolizumab and nivolumab 
or the MEK (mitogen-activated protein kinase) inhibitors trametinib and cobimetinib are new 
agents proposed in melanoma therapy [13]. Associations of BRAF inhibitors (dabrafenib) and 
MEK inhibitors (trametinib) have also been evaluated in order to improve overall survival and 
to delay the appearance of drug resistance in patients with metastatic melanoma with BRAF 
mutations [14].
In nonmelanoma skin cancer, the therapy is different depending on the severity of the tumor. 
Standard excision or Mohs micrographic surgery (MMS), radiotherapy, photodynamic ther-
apy (PDT), cryosurgery and topical treatment with imiquimod or 5-fluorouracil are employed 
in the management of this type of skin cancer [15].
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Despite the numerous studies and the advances in targeted therapy and immunotherapy, 
the treatment options in melanoma are limited [9]. The main inconveniences of chemothera-
peutic agents currently used in skin cancer are the severe side effects and the multi-drug 
resistance [16].
Due to these disadvantages of conventional therapies, new alternatives have been inves-
tigated in order to find compounds that can serve for the synthesis of new drugs [16]. 
Plant-derived compounds are intensively studied as anticancer agents, many studies 
being performed to evaluate their properties in different types of cancer, including skin 
cancer [17].
2. Plant sources of pentacyclic triterpenes with lupane scaffold
Plants have gained over the time an important place in the prevention and treatment of vari-
ous medical conditions. Extracts from plants were obtained since ancient times following sim-
ple procedures and used as teas, potions and ointments in an attempt to alleviate pain and to 
cure diseases. Natural sources of drugs remain an important branch in pharmaceutical drug 
discovery and therapeutic implementation. Combinatorial chemistry as an initial source of 
information was unable to offer the expected amount of final products, but is considered a tool 
for preliminary analysis of new drugs even on cancer treatment. Several groups of researchers 
provided routes to refine and improve the skeleton of natural compound and to prepare novel 
active agents [18]. Links between natural sources, synthetic chemistry and knowledge about 
genetic analysis of microbes are new trends in preclinical evaluations [18, 19]. Drugs derived 
from nature may be fall in one of the following categories: natural product botanical, derived 
from natural product or made by total synthesis but with the specification that the pharmaco-
phore is in relation with a natural product [18].
During the last decades, natural remedies are engaged in an unprecedented evolution aimed 
at an increased efficacy. The development of sophisticated technologies in the fields of phy-
tochemistry, drug formulation and pharmacology, as well as the focus on the mechanism of 
action on a cellular and molecular level, enables the obtainment of highly efficient drugs from 
plants.
One of the numerous categories of plant phytochemicals are triterpenes (Figures 1–3). So far, 
over 20,000 triterpenes have been isolated from the plant kingdom. They include a variety 
of structural subtypes: squalene, lanostane, dammarane, tetranortriterpenoids, lupane, ole-
anane, ursane, hopane and other [20, 21]. Pentacyclic triterpenes, their natural sources and 
biological effects are presented in Table 1.
Among plant sources containing lupan-skeleton pentacyclic triterpenes (Figure 2), birch 
bark has received particular attention due to its high content in these substances, its well-
proven application and uses over the time [41]. Currently, it is acknowledged that the 
outer birch bark is a rich source of pentacyclic triterpenes, which include: betulin (B lup-20 
(29)-ene-3β, 28-diol), betulinic acid (BA, 3β acid, hydroxy-lup-20 (29)-en-28-oic) and lupeol 
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(L, Lup-20 (29)-en-3-ol). The development of birch bark extracts, their applications and 
bioactivity has comprehensively been reviewed [42]. By analyzing birch bark extract, it 
was shown that betulin is present in the highest amount, while betulinic acid content is 
lower. However, it is possible that plants from different geographical regions present a 
variable content in pentacyclic triterpene, which requires a rigorous analysis of the content 
[43]. Differences between barks of birch species regard the content in: betulin, betulinic 
acid, betulinic aldehyde, lupeol, oleanolic acid, oleanolic acid 3-acetate, betulin 3-caffeate, 
erythrodiol and other.
Figure 1. Triterpene structures (a) lupane; (b) oleanane; (c) ursane; (d) hopane; (e) lanostane; (f) dammarane and (g) 
quassin.
Figure 3. Other triterpenes (a) ursolic acid; (b) oleanolic acid and (c) maslinic acid.
Figure 2. Lupan skeleton triterpenes (a) betulinic acid; (b) betulin and (c) lupeol.
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Substance Plant (family) Plant part Study/effect Reference
BA Ziziphus mauritiana Lam. 
(Rhamnaceae)
Stem bark In vitro—inhibitory effect on (MEL-1, 
-2, -3, -4) cells; apoptotic effect on 
MEL-2 cells
In vivo—antitumor effect on athymic 
mice injected with MEL-2 cells
[22]
BE, LU Betula x caerulea Blanch., Betula 
cordifolia Regel, Betula papyrifera 
Marsh., Betula populvolia Marsh. 
(Betulaceae)
Bark N/A [23]
BA, LU, BE, 
UA, OA
Syzygium formosanum Hay. Mori 
(Myrtaceae)
Leaves N/A [24]
BE, BA, UA Diospyros leucomelas Poir. 
(Ebenaceae)
Leaves In vivo—anti-inflammatory activity on 
Swiss mice, for induced ear edema and 
induced paw edema
[25]
OA Rosa canina L. (Rosaceae) Rose hip, 
powder
In vitro—immunomodulatory activity 
on Mono Mac 6, obtained when a 
mixture of OA, BA and UA was used
[26]
BA Rosmarinus officinalis L. (Labiatae) Stems and 
leaves
In vivo—antidepressant-like effect 
in the TST, for Swiss mice; anti-
immobility effect
[27]
BE, BA Betula pendula Roth, syn. Betula 
verrucosa (Betulaceae)
Bark In vitro—cytotoxic effect in EPG85-257 
and EPP85-181 cells line
[28]
A, BA, BE, 
LU, UA, OA
Ligustrum pricei Hayata, Ligustrum 
sinense Lour., Ligustrum lucidum 
W.T.Aiton (Oleaceae)
Leaves In vivo—analgesic and anti-
inflammatory effect on Sprague 
Dawley rats
[29]
OA, BA Viscum album L. (Santalaceae) – 
harvested from Malus domestica 
Borkh.
Sprout In vitro—cytotoxic and apoptotic effect 
on B16.F10 cells
[30]
OA, BA Viscum album L. (Santalaceae) – 
harvested from Malus domestica 
Borkh.
Sprout In vivo—antiapoptotic, antiproliferative 
effect on C57BL/6NCrL mice injected 
with B16.F10
[31]
BE, UA Myrica cerifera L. (Myricaceae) Bark In vitro—cytotoxic activity against 
HL60, A549 and SK-BR-3 cell lines
[32]
LU Taraxacum sp. Dandelion 
(Asteraceae)
Root In vitro—cytostatic, not cytotoxic effect 
on B16 2F2 cells; inhibition of cells 
proliferation by differentiation
[33]
LU Lactuca indica L. (Asteraceae) N/A In vivo—prevents local tumor 
progression, distant metastasis in dogs 
with COMM
Dogs: two miniature Dachshunds, two 
Beagles, two miniature Schnauzers, 
one Golden Retriever, one Labrador 
Retriever, one American Cocker 
Spaniel, one Cavalier King Charles 
Spaniel and 1 mixed-breed dog
[34]
LU Lactuca indica L. (Asteraceae) N/A In vivo—tumor growth suppression 
and induced cell cycle arrest in C57BL/6 
mice injected with B16 2F2 cells
[35]
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3. Obtainment of lupane-skeleton triterpenes with efficacy in  
skin cancer
Pentacyclic triterpenes from plants are secondary metabolites with high lipophilicity. 
Therefore, they are mainly located in hydrophobic histological structures. In the cork of 
trees, which represents the outer tissue of the secondary bark, triterpenes are associated with 
suberin; a well-known example is birch bark [44]. Triterpenes are as well components of cutic-
ular and epicuticular waxes covering leaves [45] and fruits [46].
Betulin was isolated for the first time in the 1788 by Lowitz [47] from birch cork. The elucidation 
of its structure was performed by only in 1953 by Guider et al. [48]. Additional plant sources for 
betulin include hornbeam (Carpinus betulus L) and hazel (Corylus avellana L.), plants which are 
phylogenetically closely related to birch [49]. Betulinic acid, a triterpene of major therapeutic 
relevance, was isolated under the name of “graciolon” from Gratiola officinalis [50] and recog-
nized as such only 40 years later [51]. “Platanolic acid,” isolated from Platanus acerifolia bark [52], 
proved later to be betulinic acid as well [53]. Furthermore, betulinic acid could be obtained from 
an alcoholic extract of Cornus florida L. bark [54]. Ko and co-workers [55] used mistletoe (Viscum 
album) to obtain an ethanol extract enriched in triterpenes, including betulinic acid and botulin.
The obtainment of triterpenes from the plant matrices employs as a first step extraction with 
organic solvents such as methanol or ethanol [56]. Other solvents are chloroform, dichloro-
methane, ethyl acetate, petroleum ether or various mixtures thereof, in accordance with the 
low polarity of these phytocompounds. Recovery procedures may include Soxhlet extraction, 
Substance Plant (family) Plant part Study/effect Reference
LU Bombax ceiba L. (Malvaceae) Stem Bark In vitro—antiangiogenic effect on 
SK-MEL-2, A549 and B16-F10 cell lines
[36]
BA, OA Paeonia rockii ssp. rockii T.Hong & 
J.J.Li (Paeoniaceae)
Root In vitro—antiapoptotic effect induced 
selectively in the M-14 cell line
[37]
UA Salvia officinalis L. (Lamiaceae) N/A In vivo—antiprotease and 
antimetastatic effects on C57BL/6N 
mice injected with B16 cells
[38]
BA Avicennia officinalis L. 
(Acanthaceae)
Leaves In vivo—anti-inflammatory effect on 
rats
[39]
BA, UA, MA Bridelia cambodiana Gagnep. 
(Phyllanthaceae)
Whole 
plant
In vitro—cytotoxic effect against HL60 
and LCC cell lines
[40]
BA (betulinic acid); BE (betulin); LU (lupeol); UA (ursolic acid); OA (oleanolic acid); MA (maslinic acid); N/A (not 
applicable); MEL-1, -2, -3, -4 (human melanoma cell line); Mono Mac 6 (human monocytic cell line); TST (tail suspension 
test); EPG85-257 (human gastric carcinoma cell line); EPP85-181 (human pancreatic carcinoma cell line); B16.F10 (murine 
melanoma cell line); HL60 (human promyelocytic leukemia cell line); A549 (human lung carcinoma cell line); SK-BR-3 
(human breast cancer cell line); B16 2F2 (mouse melanoma derived subclone with high differentiation capability); 
COMM (canine oral malignant melanoma); SK-MEL-2 (human melanoma cell line); M-14 (human melanoma cell line); 
B16 (mouse melanoma cell line derived from spontaneous skin tumor); LLC (mouse lewis lung carcinoma).
Table 1. Bioactivity of various plant products containing pentacyclic triterpenes.
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maceration and ultrasound-assisted processes [57]. In order to progressively enrich/isolate 
triterpenes, the usual phytochemical approaches are employed: partition among solvents of 
increasing polarity, column chromatography on silica gel, countercurrent chromatography 
and preparative chromatography. Triterpene acids are extracted after alkalinization with 
sodium hydroxide [57] or calcium hydroxyde [58]. Pure betulin was prepared from a crude 
mixture using a chromatographic column with silica gel as a stationary phase and a mixture of 
hexane and ethyl acetate as eluent, followed by recrystallization from 75% ethyl alcohol [59]. 
An effective preparation of crystalline betulin (99% purity) from birch bark is clearly described 
in a recent work, following the steps to remove betulinic acid and lupeol. Additionally, the 
authors demonstrate the obvious relationship between the cytotoxic activity of betulin and 
its purity [58]. The analytic determination of triterpenes in samples is performed by reverse-
phase HPTLC and gas chromatography, coupled with the detection using mass spectrometry 
detection, is a widely used method for analysis of betulin and other triterpenes in samples. 
High-performance thin-layer chromatography (HPTLC) is a valuable straightforward tool for 
the visualization of impurities [60].
Betulinic acid received high attention due to its properties to inhibit the growth of cancer cell 
lines, without being cytotoxic to normal cells. In plant materials used as sources of triterpenes 
such as birch, the content in betulinic acid is much lower than that in betulin. For this reason, 
various attempts have been made to obtain betulinic acid, using betulin as a starting point. In 
the study of Melnikova and co-workers [61], the most intense catalytic activity was noticed for 
aluminum salts, which also have a selective activity. The reaction proceeds via the intermedi-
ate betulonic acid, purified by recrystallization. Betulonic acid is reduced with NaBH
4
 (THF 
or isopropanol) at room temperature to obtain a mixture of 3α-betulinic acid and betulinic 
acid-3β [61].
Enzymatic transformations, privileged for their simplicity, eco-friendliness and safety, are cur-
rently a mainstay in the obtainment of drugs. In an enzymatic approach, the fungus Armillaria 
luteo-virens Sacc ZJUQH100-6 was employed in the biotransformation of betulin into betulinic 
acid [62]. Optimization of the obtainment was monitored by variation of parameters like pH, 
glucose, betulin content, addition of tween 80 and stage of inoculation; the presence of the 
surfactant had a significant impact on the yield of the biotransformation.
While betulin is readily available from birch and other plants, its anticancer activity is only 
moderate. Being an accessible starting point for derivatizations, betulin has been the subject 
of many researches, aiming to obtain compounds with enhanced anticancer activities [63]. 
The acetylated derivates were tested for antiproliferative effect on several cell lines: colorec-
tal adenocarcinoma, leukemia and breast cancer. By esterificating betulin with propionic acid 
in dichloromethane solution in the presence of dicyclohexylcarbodiimide and 4-dimethyl-
aminopyridine, derivatives: 28-O-propynoylbetulin and 3.28-A, IB, dipropynoylbetulin were 
obtained. Column chromatography was employed in order to obtain the pure components with 
a yield of 60% in the case of the first derivative and 12% in the second. The reaction of betulin 
with propargyl chloroformate and 3-butyl-1-yl chloroformate in benzene, in the presence of 
pyridine, resulted in the formation of a mixture of 28-O-propargyloxycarbonylbetulin mono-
esters and 28-O- (3-butynyloxycarbonyl) toxin and di-3,28-A sheep-di (pro-pargyloxycarbonyl) 
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3.28-A toxin and sheep-di (3-butyn-yloxycarbonyl) toxin. The resulting mixture was separated 
by column chromatography; thus, pure components were obtained in a 64–69% yield for mono-
esters and 23–27% in the case of diesters [64].
4. Advanced formulation of lupane triterpenes
The most challenging aspect of the biomedical use of lupane triterpenes is their low water 
solubility which subsequently causes poor bioavailability [65]; so far, several delivery systems 
have been developed in order to achieve superior pharmacokinetic outcomes. The current 
subchapter aims to review the most recent and promising delivery options for betulin, betu-
linic acid and lupeol.
The first step in the attempt to modulate the aqueous solubility of an insoluble compound 
relies in its convenient derivatization with water-soluble partners; such an attempt was con-
ducted by Drag-Zalesinska and co-workers [66], who prepared mono- and diesters of betulin 
and betulinic acid with amino acids. All esters revealed higher water solubilities and significant 
cytotoxic activity via apoptosis induction; the type of ester as well as the type of the amino 
acid side chain strongly influences the biological effect of the respective compounds [66]. C(2)-
propargyl-substituted pentacyclic triterpenoids conjugated with 1,2,3-triazole glucopyrano-
sides were synthesized via “click” chemistry in order to achieve optimized water solubility as 
well as pharmacokinetic and pharmacological properties [67].
Cyclodextrin (CD) complexation represents an attractive solution to increase the aqueous sol-
ubility of numerous compounds; through their hydrophobic interior and hydrophilic surface, 
cyclodextrins are able to accommodate various lipophilic guest molecules which can thus 
be water-solubilized. According to molecular studies [68], the bulky structures of betulinic 
acid and betulin fit best inside the cavity of γ-CD and its semisynthetic derivatives, such 
as hydroxypropyl-γ-CD (HPGCD). As a result of HPGCD complexation, a 14-fold increased 
water solubility was reported for BA accompanied by superior biological activity [69], i.e., 
strong antiangiogenic and antitumor effect [70, 71]. Similar outcomes were achieved in terms 
of anti-melanoma activity tested on B16 cell line (murine melanoma) [72]. Fontanay et al. 
conducted a study on the inclusion of hydroxy pentacyclic triterpenoid acids, including BA, 
inside native γ-CD [73]; the physicochemical analysis revealed the formation of a 1:1 complex 
with a significantly improved aqueous solubility.
β-CD derivatives also served as complexation partners for BA, and its inclusion in the cyclo-
dextrin hydrophilic matrix led to significantly improved dissolution rate and, subsequently, 
antiproliferative in vitro activity against MCF7 (breast cancer) cell line [74]. The same tumor 
cell line was involved in the study of the biological activity of betulinic acid accommodated 
inside native β-CD [75]; a dose-dependent antiproliferative activity was reported, through 
mitochondria-mediated apoptosis induction and G2/M cell cycle arrest.
An important parameter in the cyclodextrin inclusion process is the stability constant of the 
final complex, its value giving the measure of the potential use of the complex as biologi-
cally active agent; significantly high stability constants were achieved for both betulin and 
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betulinic acid in complex with newly synthesized hydrophilic γ-CD derivatives [76]. Such 
a high stability constant characterizes a strong interaction between the host- and the guest 
molecule, thus enabling the delivery of the active drug at the target site in the absence of 
systemic adverse effects. Both complexes, with betulin and betulinic acid, respectively, were 
in vitro and in vivo tested, revealing moderate in vitro antiproliferative activity; however, in 
vivo results on murine models showed a significant decline in tumor size and volume [77, 78].
The inclusion of betulin inside HPGCD led to optimized outcomes in terms of bioavailability 
and antiproliferative activity [79, 80]; similar results were reported for betulin complexation 
with hydrophilic β-CD derivatives that caused stronger inhibitory activity against MCF7 
(breast cancer) cell line than pure betulin [74].
Lupeol was also subjected to inclusion inside γ-CD by kneading in a 1:2 molar ratio; the com-
plex revealed optimized antiproliferative and antiangiogenic activities compared to the pure 
drug [81].
The use of triterpenes as mixtures such as total extract of birch outer bark may trigger simul-
taneously various mechanisms of apoptosis induction and therefore result in an additive or 
synergistic effect. Hertrampf et al. [82] used HPBCD as solubilizer for birch total extract; a 
series of dilutions were prepared using the main ingredient, betulin, as a reference to calcu-
late concentrations. The study reported the multivalent cytotoxic activity of the birch bark 
at lower concentrations than previously used presumably due to a higher bioavailability of 
triterpenes provided by cyclodextrin solubilization; moreover, a synergistic effect was sug-
gested. Triterpene-rich mistletoe extract (6.9% BA) was solubilized by Strüh et al. [30] by using 
HPBCD and tested against B16F10 melanoma cell line; a dose-dependent reduction of cellular 
ATP was reported accompanied by high cytotoxicity due to DNA fragmentation. The research 
was continued by in vivo studies on C57BL/6 mice bearing B16F10 subcutaneous melanoma, 
revealing an increased antitumor effect and a prolonged mice survival [31].
An alternative research direction was the preparation of cyclodextrin conjugates instead of 
inclusion complexes; “click chemistry” was involved in the synthesis of triazole-bridged 
conjugates between β-CD and pentacyclic triterpenes [83]. All bioconjugates showed higher 
hydrophilicity than the parent compound, and several conjugates displayed significant 
cytotoxicity on various cancer cell lines; in addition, the cyclodextrin conjugation led to the 
disappearance of haemolytic toxicity. The authors continued their research by synthesizing 
α-CD conjugates with several pentacyclic triterpenes including BA [84]; all conjugates exhib-
ited lower hydrophobicity than the parent molecules accompanied by significant anti-HCV 
(hepatitis C virus) entry activity.
An excellent review was published in 2016 by Lima et al. [85], describing the main attempts to 
use cyclodextrins as nanocarriers for various terpenes; the authors concluded that cyclodex-
trins are feasible tools in improving the pharmacological profile of terpenes, limited mainly 
by the scarce pharmacokinetic and clinical studies.
Liposomes are small vesicles displaying one or more phospholipidic layers and an aqueous 
core [86] that may incorporate both lipophilic and hydrophilic compounds [87, 88]. Betulinic 
acid was trapped inside large liposomes by Mullauer et al. [89] and administered to mice 
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bearing experimental models of colon (SW480) and lung (A549) cancer; no systemic adverse 
effects were reported following parenteral (i.v.) and oral administration. Similar studies 
reported liposomal and proliposomal formulations with BA with 95% yield of the incorpora-
tion process [90]. Phospholipidic nanosomes prepared by means of supercritical fluids were 
used to entrap BA in order to increase its efficacy as antiviral agent [91, 92]. Several betulin 
derivatives such as 28-acetylenic derivatives [93] and pyrazoles and 1,2,3-triazole derivatives 
[94] were synthesized and formulated as liposomes; the nanoformulations exhibited strong 
apoptotic activity due to both higher biological effect of the active compound and optimized 
delivery. PEG-ylated BA liposomes were obtained by Liu et al. in 2016, entrapping BA in the 
lipid bilayer of the liposomes by the ethanol injection technique [95]; the hydrophilic outer 
PEG layer ensured improved sustained release and antitumor effect compared to free BA or 
BA liposomes.
Another attractive option in drug delivery is the use of micro- and nanoemulsions; a nano-
emulsion containing BA was prepared using flax-seed oil as lipophilic phase and the high-
pressure homogenization method [96]; the in vivo testing on the chorioallantoic membrane 
(CAM assay) revealed a significant antiangiogenic activity. The same procedure was applied 
for betulin nanoemulsion, followed by in vivo testing by CAM assay and experimental 
murine cancer model; the study reported strong anti-inflammatory, antiproliferative and 
antiangiogenic activities of the incorporated betulin as well as its potential benefits in inhib-
iting metastasis [97]. An oil-in-water nanoemulsion with BA was prepared through the use 
of phospholipase-catalyzed modified phosphatidylcholine as emulsifier in an ultrasound 
device; various factors such as composition, ultrasound amplitude, temperature and pH sig-
nificantly influenced nanoparticle size and stability [98].
A different approach consists in the administration of betulin via the nasal route; in order to 
avoid mouth sedimentation of betulin particles, the solvent exchange method was used to 
limit particle sizes to nanoscale, thus leading to higher bioavailability of betulin in the lower 
respiratory tract [99].
Water solubility may be increased through grinding with hydrophilic polymers (i.e., polyvi-
nylpyrrolidone, polyethylene glycol, arabinogalactan) [100, 101]; solid dispersions of BA with 
various hydrophilic polymers (i.e., Soluplus, HPMCAS-HF, Kollidon VA64, Kollidon K90, 
Eudragit RLPO) in 1:4 (w/w) ratio were prepared and analyzed by Yu et al. [102] in 2014, reveal-
ing a great potential to increase BA water solubility. Moreover, hydrophilic bioconjugates can 
be synthesized between active drugs and hydrophilic polymers. BA-monomethoxy polyeth-
ylene glycol (mPEG) conjugate was synthesized by covalent bonding of the carboxyl moiety 
of BA and the amine groups of mPEG [103]; the conjugate exhibited cytotoxicity through cell 
apoptosis on hepatic cancer cells (Hep3B, Huh7) as well as in vivo antitumor efficacy in Ehrlich 
ascites tumor (EAT) model while lacking any sign of biochemical and histological toxicity. 
A step further was represented by the use of multiarm-PEGs as conjugation partner which 
offer a high density of functional groups; through the formation of an ester bond, BA was 
linked to eight-arm PEG (8arm-PEG) and then to a targeting molecule (folate) followed by 
the self-assembly into nanoparticles [104]. A second anticancer drug, hydroxycamptothecin, 
was added by nanoprecipitation; the ensemble achieved a dramatically increased cytotoxicity, 
prolonged blood circulation, enhanced tumor targeting and lower systemic toxicity than the 
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free drugs; in addition, a synergistic antitumor efficacy was reported [104]. BA also shows the 
ability to self-assemble into nano- and microfibers with antileukemic efficacy and cytoprotec-
tive activity as well [105].
Biodegradable polymeric nanospheres based on poly(lactide-co-glycolide)-poly(ethylene 
glycol) (PLGA-PEG) were prepared by nanoprecipitation to incorporate 40% BA [106]; 
the study reported an increased cytotoxicity and lower IC50 value compared to the pure 
drug. PLGA was used as building material by interfacial deposition for nanocapsules that 
efficiently entrapped lupeol [107]. Polymer matrixes can be involved in regional chemo-
therapy, an approach that avoids systemic adverse effects [108] and allows the controlled 
release of the pure drug; betulin was incorporated as model compound in such a matrix 
(poly(3,4-ethylenedioxythiophene), its release being conducted by passive or active mode. 
The novel formulation exhibited efficient cytotoxic activity against KB and MCF7 cancer 
cell lines.
BA conjugates with carboxyl-functionalized single-walled carbon nanotubes were synthe-
sized via π–π stacking interaction, leading to a 20% loading of the active drug [109]; follow-
ing physicochemical and biological analysis, the authors reported the controlled, prolonged 
release of the drug, with no sign of toxicity on normal fibroblasts and significant cytotoxic-
ity against A549 (lung cancer) cell line. The research continued by coating the nanotubes 
with four biopolymers: tween 20, tween 80, polyethylene glycol and chitosan in order to 
further improve biocompatibility [110]; the procedure induced sustained and prolonged 
release compared to the uncoated nanotubes, while cytotoxicity depended on the chosen 
biopolymer.
Metallic nanoparticles were also used as nanocarriers for pentacyclic triterpenes; as an 
example, magnetic nanoparticles coated with chitosan were loaded with BA and exhibited 
a pseudo-second-order kinetic model release of the active drug [111]; the nanoparticles were 
cytotoxic on MCF7 cells in a dose-dependent manner while lacking toxicity against normal 
mouse fibroblast cells. Silver nanoparticles coated with BA were involved in the in vitro test-
ing on a panel of cancer cell lines, including A375 (murine melanoma) [112]; the new for-
mulation revealed strong antiproliferative and antimigratory activity, in particular against 
melanoma cells.
5. Innovative approaches in preclinical evaluations of pentacyclic 
triterpenes of the lupane series in skin cancer
Preclinical trials are important in the initial evaluation of new drugs, formulations or specific 
new design of pathology. They are complex processes with an uncertain ending, as just a 
reduced percent of evaluations lead to a market product. It is estimated that around 90% of 
tested drugs are not launched to the market [113]. Despite intense of basic research, the actual 
delivery of accepted drugs is scarce.
The classical route of a tested compound in preclinical trials includes in vitro tests followed 
by in vivo tests on animals [113]. These tests may be conceived in a variety of ways and are 
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constantly improved and diversified. The mainstay of preclinical tests regarding a potential 
efficacy against skin cancer types is in vitro tests using different types of cell lines. In this 
regard, lupane triterpenes were tested on human melanoma (G361, SK-MEL-28, MEL-2, 
SK-MEL2, A375), mouse melanoma (B16-F1, B16 2F2) and human skin epidermoid carci-
noma A431. In case of betulin, the latter showed a particularly high sensitivity (with a IC50 
value below 10µM), while various types of human melanoma cell lines may display a high 
variation range of the sensitivity to betulin, with differences in IC50 values of one order 
of magnitude, from 12.4 to over 250 µM [114]. For betulinic acid, IC50 was 154 µM when 
tested on A375 melanoma [115], and 70 µM when tested on B16-F10 murine melanoma 
[116]. Information of particular relevance for the actual clinical utilization as anticancer 
agent comes from comparative data on the cytotoxicity against normal cells and cancer 
cell lines. Betulin, for example, is more cytotoxic against cancerous cells than nontumoral 
ones [114]. Further steps in preclinical evaluation are the investigation of the mechanism 
of action; lupeol, betulin, betulinic acid and their semi-synthetic derivatives have so far 
shown significant effects on apoptosis and cell cycle regulation [117, 118]. As inflamma-
tion is an important player in the pathogenesis of cancer, the anti-inflammatory effects and 
mechanisms are as well explored to give a correct picture of the antitumoral potential [117]. 
Furthermore, it is important to explore the antimigratory potential of natural products, 
as it has a seminal importance for malignant melanoma—a cancer type with a high inva-
siveness [119]. A global approach to relevant preclinical tests regarding triterpenes should 
thus be multi-component. In this regard, our workgroup has established an efficient battery 
of tests for aimed at establishing the potential of natural triterpenes with anticancer/anti-
inflammatory activity as agents against skin cancer. The module of preclinical evaluations 
includes as follows:
• Step 1: in vitro tests on normal cells (e.g., HaCat) comparing with specific pathological tests; 
evaluation of cytotoxic activity;
• Step 2: in vitro evaluations concerning the impact on apoptosis, and observations of specific 
markers via DAPI/HOPI staining, and evaluation of Annexin V, caspases and other cellular 
markers [120];
• Step 3: in vivo embryonated egg membrane assay for toxicological evaluation (HET CAM 
assay) and investigations of the potential to affect angiogenesis; future aspects include culti-
vation of cancer cells on embryonated eggs and direct research of the therapeutic potential;
• Step 4: in vivo tests including a large number of experimental protocols: photochemical 
model, inoculation of murine cells, xenograft of human pathological cells on adequate 
mouse hosts and correlations with therapeutical surveillance. Furthermore, histopath-
ological evaluations and immuno-histochemical assays are correlated with innovative 
approaches like RAMAN skin evaluation, noninvasive methods for skin quality and sur-
face damage characterization.
Additional determinations could require selection of cells from a primary experimental 
tumor, cultivation of cells and evaluation of compounds, PET animal observations and other 
methods applied for a detailed pathologic surveillance of drugs.
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6. Pentacyclic triterpenes: mechanism of action at cellular and  
molecular level
Apoptosis is a programmed cell death consisting in morphological changes including cell 
shrinkage, nuclear condensation, chromosomal DNA fragmentation, plasma membrane bleb-
bing and caspase activation [121]. In this regard, apoptosis is considered a crucial physiologi-
cal process in tumor clearance, being a major target for anticancer drugs [122]. The molecular 
mechanisms of apoptosis can include extrinsic and intrinsic pathways. The extrinsic pathway 
of apoptosis is initiated by external signals, which can activate TNF/Fas-receptor, which in 
turn activates procaspase-8 [123]. The activated caspase-8 is involved into the caspase-3, -6 
and -7 cascade activation [124]. Caspases are important cellular enzymes synthesized as inac-
tive zymogens, which can be activated into their active tetrameric forms by various apoptotic 
signals [124]. The activation of caspase-3, -6 and -7 leads to cell death not only by breaking 
down the cytoskeleton, but also the nucleus.
The intrinsic pathway of apoptosis, known as the mitochondrial pathway, is initiated by inter-
nal stimuli which can activate the proapoptotic genes from the outer membrane of mitochon-
dria. Bcl-2 family proteins (Bax, Bak, Bcl-xs) are important proapoptotic genes involved in 
permeabilization of the mitochondrial membrane in order to release cytochrome c in cyto-
sol, where it binds to the caspase-activating protein apoptotic protease activating factor-1 
(Apaf-1) and with the procaspase-9, transforming into an apoptosome [124]. The apoptosome 
releases the activated form of caspase-9, which is also involved into the caspase-3, -6 and -7 
activations, which lead to cell death [123].
Previous evidences showed that the pentacyclic triterpens, especially betulin, betulinic acid, 
lupeol and ursolic acid, have induced apoptosis in different types of cancer cells via activation 
of the mitochondrial pathway and not to the death receptor pathway (extrinsic way) [125, 126]. 
These data have been supported by Drag-Zalesinska et al. [118] study in which betulin and betu-
linic acid proved to induce apoptosis in human metastatic melanoma cells (Me-45) by releasing 
cytochrome c or the apoptosis inducing factor (AIF) through the mitochondrial membrane. Liu 
et al. [122] have also demonstrated that betulinic acid, as well as betulin, could kill CNE2 cells 
through the mitochondrial pathway. Betulinic acid induced the DNA fragmentation, caspase 
activation and cytochrome c release but independent of Bax proteins [115, 122]. Moreover, betu-
linic acid has been also involved in activation of nuclear factor kappa B (NF-κB) responsible for 
apoptosis in various types of cancer cells [127].
The increased production of reactive oxygen species (ROS) caused by betulin and betulinic 
acid stimulation [128, 129] has been considered a stress factor involved in the depolar-
ization of mitochondrial membrane [130]. Furthermore, both calcium overload and ATP 
depletion were additional stress factors responsible for increasing the permeability of the 
inner mitochondrial membrane through formation of nonspecific pores [116]. For instance, 
the dimethylaminopyridine triterpenoid derivatives have also caused the depolarization 
of the mitochondrial membrane in situ, in order to increase the permeability transition 
pore [131].
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Figure 4. The mechanism of action of betulinic acid and betulin in skin cancer.
Unlike the previous data, the study of Şoica et al. [77] on B164A5 murine melanoma cells and 
on a mouse melanoma model showed that BE and its derivatives had no effect on caspase-2 
regulation, the apoptotic mechanism of betulin being suggested to be probably through the 
transformation of BE into betulinic acid inside the cells.
According to the study of Muceniece et al. [132] in vitro, betulin had a mimetic effect on mel-
anocortin (MC) receptor, especially on MC-1 subtype. This observation has been also sup-
ported by Şoica et al. [77] study in which botulin had revealed strong inhibitory effects on 
B64A5 murine melanoma cells, by binding to the melanocortin receptors. Betulin has been 
not involved by itself in stimulation of cAMP generation, but it acted as a weak antagonist on 
alpha-melanocyte-stimulating hormone (alpha-MSH)-induced cAMP accumulation in B16-F1 
mouse melanoma cells [132].
In vitro and in vivo studies have also revealed that the birch bark extract and betulin have sig-
nificantly increased the expression of PARP-1 in melanoma cells [118], exhibiting interferon-
inducing activity [133].
According to Zhang et al. [126] study, betulinic acid induced apoptosis by suppressing the 
cyclic AMP-dependent transcription factor ATF-3 and NF-κB pathways and decreasing the 
expression of topoisomerase I, p53 and lamin B1. On one hand, earlier studies indicated that 
betulinic acid had induced apoptosis of cells due to the p53 pathways [134]. This conclusion 
has been also supported by Tiwari et al. [135] study, in which BA proved a dose-dependent 
apoptotic effect on both p53 mutant and wild-type cells probably because of its involvement 
in p53-independent apoptotic pathway. On the other hand, a recent study has shown that the 
apoptotic effect of betulinic acid in human metastatic melanoma cells (Me-45) had been inde-
pendent of p53-apoptotic pathway [118]. The presumable mechanisms of action of betulinic 
acid and betulin in skin cancer are depicted in Figure 4.
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Lupeol is a complex multitarget phytochemical, being involved in controlling IL-1 receptor-
associated kinase-mediated toll-like receptor 4 (IRAK-TLR4), Bcl-2 family, nuclear factor 
kappa B (NF-κB), phosphatidylinositol-3-kinase (PI3-K)/Akt and Wnt/β-catenin signaling 
pathways [136]. According to the Tarapore et al. study, the anticarcinogenic effect of lupeol 
has been related to the Wnt/β-catenin signaling pathway. That study has revealed that 
lupeol caused a dose-dependent decrease in Wnt target genes in Mel 1011 cells. Moreover, 
there has been also observed a decrease of nuclear β-catenin expression, associated with an 
enhancement of plasmatic β-catenin expression in melanoma cells (Mel 928 and Mel 1241). 
Consequently, lupeol has been involved in blocking the movement of β-catenin between cyto-
plasm and nucleus [137].
An in vivo study on Swiss Albino mice showed that lupeol exerted apoptotic effects through 
the enhancement of bax and caspase-3 genes expression and downregulation of bcl-2 anti-
apoptotic genes [138].
Unlike botulin and betulinic acid, lupeol has also induced apoptosis via extrinsic pathway by 
enhancing the expression of FADD protein and Fas receptors [127].
Ursolic acid has strongly increased the IR-induced apoptotic effect in various types of cancer 
cells, likely DU145, CT26 and B16F10, playing a major role in DNA fragmentation, mitochon-
drial dysfunction and apoptotic marker modulation [139]. Moreover, ursolic acid has induced 
apoptosis in M4Beu cells human melanoma through intrinsic pathway by enhancing the cas-
pase-3 activity in a dose-dependent manner, correlated with a low caspase-9 activity [140]. 
Ursolic acid has also proved to act as an inhibitor of the endogenous reverse transcriptase 
(RT) activity in the following tumor cells: melanoma (A375), glioblastoma (U87) and thyroid 
anaplastic carcinoma (ARO), as well as on nontransformed human fibroblast cell line (WI-38), 
exhibiting strong antiproliferative effects [141].
The mechanism of apoptosis induced by pentacyclic triterpens is not fully understood, 
although, according to the previous studies, we can conclude that these triterpens exhibited 
strong apoptotic effects, especially via intrinsic pathway, being involved in increasing the 
permeability of inner mitochondrial membrane, activation of caspase-9 and 3, as well as cell 
death.
7. Conclusion
Pentacyclic triterpenes represent an important issue in the field of antiskin cancer formula-
tions; nowadays, the researches focus on the development of nanoformulations that provide 
multiple advantages over the classical pharmaceutical formulations, including the possibility 
of being decorated with targeting moieties that significantly improve the antiproliferative 
activity of the loaded active drug. Different mechanisms of action have been identified so far 
at cellular and molecular level, in particular for betulinic acid; however, future studies are 
needed in order to fully comprehend the intimate details of the anticancer treatment with 
pentacyclic triterpenes and formulations thereof.
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